Horizon 2010 Horizon 2010 builds on the success of our 5X5 goals and covers the period from 2006 to 2010. We are focusing our efforts and resources now to achieve the kind of revenue and earnings growth necessary to remain a leading company beyond 2005. Our Horizon 2010 vision and goals will help ensure that we are solidly positioned to continue our 29-year mission of discovering, developing, manufacturing and commercializing life-enhancing and life-saving medicines for patients with unmet medical needs.

Our Vision Utilize the science of biotechnology to become a leader in revolutionizing the treatment of patients with cancer, immunological diseases and angiogenic disorders.

Our Goals

• Aim to become the number one U.S. oncology company in sales by 2010.
• To position ourselves for continued leadership in our oncology business by bringing five new oncology products or indications for existing products into clinical development and into the market.
• To build a leading immunology business by expanding the fundamental understanding of immune disorders, bringing at least five new immunology products or indications into clinical development, and obtaining U.S. Food and Drug Administration approval of at least five new indications or products by 2010.
• To increase our leadership in developing biotherapeutics for disorders of tissue growth and repair, with a major focus on angiogenic disorders, and to move at least three new projects into late-stage research or developmental research and three or more new projects into clinical development by 2010.
• To achieve average annual earnings per share growth rates sufficient to be considered a growth company.